Moelis & Company (MC) Forms $51.83 Double Top; Epizyme Has 1.21 Sentiment

Moelis & Company (MC) formed double top with $55.97 target or 8.00% above today’s $51.83 share price. Moelis & Company (MC) has $2.90B valuation. The stock decreased 2.13% or $1.125 during the last trading session, reaching $51.825. About 1.44M shares traded or 340.28% up from the average. Moelis & Company (NYSE:MC) has risen 40.93% since March 13, 2017 and is uptrending. It has outperformed by 24.23% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.45 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

The stock increased 13.05% or $2.41 during the last trading session, reaching $20.86. About 232,870 shares traded. Epizyme, Inc. (EPZM) has risen 91.85% since March 13, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

Since January 1, 0001, it had 1 insider buy, and 3 sales for $1.35 million activity.

Foresite Capital Management Ii Llc holds 11.92% of its portfolio in Epizyme, Inc. for 1.54 million shares. Palo Alto Investors Llc owns 6.40 million shares or 5.13% of their US portfolio. Moreover, Nea Management Company Llc has 4.31% invested in the company for 6.46 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 1.19% in the stock. Oracle Investment Management Inc, a Connecticut-based fund reported 369,403 shares.

Analysts await Moelis & Company (NYSE:MC) to report earnings on April, 24. They expect $0.65 EPS, up 20.37% or $0.11 from last year’s $0.54 per share. MC’s profit will be $36.41M for 19.93 P/E if the $0.65 EPS becomes a reality. After $0.52 actual EPS reported by Moelis & Company for the previous quarter, Wall Street now forecasts 25.00% EPS growth.

Among 13 analysts covering Moelis & Co (NYSE:MC), 6 have Buy rating, 0 Sell and 7 Hold. Therefore 46% are positive. Moelis & Co has $60 highest and $24 lowest target. $40.13’s average target is -22.57% below currents $51.825 stock price. Moelis & Co had 32 analyst reports since August 11, 2015 according to SRatingsIntel. On Thursday, February 8 the stock rating was maintained by Bank of America with “Buy”. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Sunday, August 27 report. The rating was maintained by JMP Securities on Tuesday, July 25 with “Market Outperform”. Buckingham Research upgraded the shares of MC in report on Wednesday, January 13 to “Buy” rating. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, October 26. JMP Securities maintained it with “Market Outperform” rating and $47 target in Thursday, October 26 report. The firm has “Hold” rating given on Wednesday, February 7 by Keefe Bruyette & Woods. Wood upgraded the shares of MC in report on Tuesday, August 11 to “Market Perform” rating. The stock of Moelis & Company (NYSE:MC) earned “Outperform” rating by Bruyette & Woods” on Tuesday, August 11. The rating was upgraded by Credit Suisse on Tuesday, September 8 to “Neutral”.